GLAXOSMITHKLINE popularity and GLAXOSMITHKLINE trends
You need to upgrade your Flash Player
- News
- Tweets
- Youtube
- DIGG's
- Amazon
- FB
- Domains
- eBay
- Pictures
- Wikipedia
- Tracks
- MIX
- glaxosmithkline.com
- T-shirts
Irish Times
Glaxo strategy to buy collaborator firms
GLAXOSMITHKLINE may find its next acquisition target where the UK drug-maker found the last two: among more than a dozen companies it collaborates with to develop new treatments.
|
Les Echos
GlaxoSmithKline demande à Human Genome de retirer sa pilule empoisonnée
GlaxoSmithKline (GSK) a annoncé hier avoir modifié les conditions de son OPA sur la société américaine de biotechnologies Human Genome Sciences pour tenir compte du plan de défense mis en place par sa cible. Human Genome a adopté la semaine dernière un plan visant à repousser l'attaque de GSK, avec...
|
WSJ
Human Genome adopta un plan para evitar la oferta hostil de Glaxo
Human Genome Sciences Inc. adoptó un plan de derechos de accionistas con un plan para diluír su base si alguien intenta adquirir un 15% o más de las acciones de la compañía sin la aprobación del directorio tras la oferta de compra hostil de GlaxoSmithKline PLC por US$2.600 millones.
|
Huffington Post
Dabrafenib And Trametinib: Melanoma Drug Combo Shows Promise In Small Trial
* Progression-free survival of 7.4 months * Much lower incidence of squamous cell cancer By Deena Beasley May 16 (Reuters) - Two drugs being developed by GlaxoSmithKline Plc - each designed to block different pathways used by cancer cells - have been shown in a small clinical trial to curb melanoma with fewer side effects than current therapies. ...
|
Reuters
Glaxo melanoma drug combo shows promise in small trial
(Reuters) - Two drugs being developed by GlaxoSmithKline Plc - each designed to block different pathways used by cancer cells - have been shown in a small clinical trial to curb melanoma with fewer side effects than current therapies.
|
Telegraph
GlaxoSmithKline to buy Cellzome for £61m
GlaxoSmithKline, the UK's biggest drug company, is to buy a leading protein technology company in which it already owns a 20pc stake.
|
siliconindia
GSK Healthcare Aims at Double-Digit Market Share in Oral Care
GlaxoSmithKline Consumer Healthcare (GSKCH), which re-entered the Indian toothpaste market last year launching Sensodyne, hopes to increase its share to double-digits from the current 2 percent, a top company official said.
|
webwire
Brand Equity of Niche Brands Grows Rapidly Online, BigVoice Trend Update Shows
New York, NY, May 11, 2012 - BigVoice monitors trends across various OTC categories to provide smart marketing solutions for niche brands. An analysis of the sleep aid category from late 2011 to May 2012 captured a snapshot of the rapid develo...
|
Washington Post
GlaxoSmithKline to take Human Genome Sciences buyout offer to shareholders
British drugmaker GlaxoSmithKline said Wednesday it will no longer wait for Human Genome Sciences to consider an acquisition offer and will instead appeal directly to the Rockville firm’s shareholders to accept its $13-per-share asking price.
Read full article >>
|
New York Times
DealBook: Glaxo to Make Hostile Bid for Human Genome Sciences
GlaxoSmithKline plans to take its bid for Human Genome Sciences directly to shareholders this week, after being rejected by the biotechnology company last month.
|
Reuters
GSK to go hostile with $2.6 billion Human Genome tender
LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board.
|
AP
GlaxoSmithKline in takeover bid for Human Genome
LONDON (AP) -- GlaxoSmithKline PLC has tabled an offer to take over U.S. drug maker Human Genome Sciences Inc. which values the target at nearly $2.6 billion....
|
Le Point
GSK prêt à lancer cette semaine une OPA hostile sur Human Genome Sciences
Le groupe pharmaceutique britannique GlaxoSmithKline (GSK) a annoncé...
|
Handelsblatt
Offerte : Glaxo will Human Genome übernehmen
Obwohl Human Genome die Offerte als zu niedrig zurückgewiesen hat, beginnt GlaxoSmithKline mit der Übernahme des Pharmakonzerns. Die beiden Unternehmen arbeiten bereits bei der Entwicklung von Wirkstoffen zusammen.
|
The Nation
GSK committed to Pakistan
KARACHI - GlaxoSmithKline (GSK) has reinforced its commitment to Pakistan by announcing it will increase investment in consumer health brands over the next five years, says a Press release.
It will do so via the introduction of new brands in its wellness, oral health and nutrition portfolios, said John Sayers, president of GSK Consumer Health of Asia, Pacific, Latin America and Middle East ...
|
THE AUSTRALIAN
GSK females make blue chip pink
A CHINESE banker and a US oil exec will join the GlaxoSmithKline board, giving it more women directors than other London blue-chips.
|
Daily Mail
ALEX BRUMMER: Aviva embarrassed as investors punish their own
It is enormously embarrassing for the company to find itself in the rogue’s gallery alongside the Royal Bank of Scotland, Shell and GlaxoSmithKline, all of which have suffered similar humiliations over the past decade.
|
Barrons
Glaxo Slips 3% On Weak EU Pricing
GlaxoSmithKline shares slipped 3% on weak pricing in Europe, which overshadowed the pharmaceutical companys promise to return to sales growth in 2012. Shares of Glaxo (GSK), the United Kingdoms largest drug maker were off $1.42 to $45.76 in afternoon trading. The company said first-quarter net profit was down 13% year over year, to 1.33 billion [...]
|
Irish Times
Price cuts weigh on Glaxo revenue
GlaxoSmithKline grew revenue just 1 per cent in the first quarter, reflecting pressures on its business from government price cuts in Europe and some emerging markets and tough year-ago comparisons.
|
Reuters
GSK insists it best owner for Human Genome
LONDON (Reuters) - Drugmaker GlaxoSmithKline said on Wednesday its $2.6 billion bid for long-time partner Human Genome Sciences was "full and fair" and it was the only obvious owner for the U.S. biotechnology firm.
|
THE GLOBE AND MAIL
GlaxoSmithKline struggles to grow in first quarter
Drug makers revenue advances 1% in first quarter on price cuts in Europe, emerging markets
|
WirtschaftsWoche
Aktientipp: GlaxoSmithKline: Bußgeldzahlungen gut verdaut
Der britische Pharmakonzern hat sein Geschäftsmodell erfolgreich neu ausgerichtet, ein Streit mit den USA ist beigelegt. Das sind gute Aussichten.
|
Reuters
UPDATE 1-Aspen buys GSK OTC drug brands for $263 mln
LONDON, April 20 (Reuters) - GlaxoSmithKline has
agreed to sell a clutch of international over-the-counter
healthcare brands for 164 million pounds ($263 million) to South
Africa's Aspen Pharmacare,...
|
WSJ
Embedded in Trade's DNA: Big Gains on Genome Bet
An options trader made a bet on a steep climb in Human Genome Sciences through year's end. Thursday, the trader stood to profit nearly $3.5 million, as the biotech company's shares surged after news of an unsolicited takeover bid from GlaxoSmithKline.
|
Fortune
Human Genome Sciences rejects takeover bid
Biotech firm Human Genome Sciences announced Thursday that it had rejected a takeover bid from pharmaceutical giant GlaxoSmithKline that valued it at just over 80% of its closing price Wednesday.
|
FT
GlaxoSmithKline rebuffed by Human Genome Sciences
US developer of antibody drugs says offer ‘does not reflect value inherent in HGS’ but launches strategic review that will consider sale
|
The Guardian
MPs' £1.8m in perks revealed
Guardian research finds that gifts and funding included trips to 27 countries and £32,000 donation to parliamentary choirDonations to all-party parliamentary groups: get the data Businesses, overseas governments and lobby groups have given sponsorship, free gifts and funding worth at least £1.8m to MPs and Lords in the past year through all-party parliamentary groups, Guardian research has reve...
|
Hoy
James Murdoch se despide de Londres
James Murdoch, de 39 años, anunció ayer su dimisión como presidente de la televisión BSkyB, el último puesto que tenía en Londres, donde ya había dimitido como consejero delegado de News International, firma gestora de los periódicos británicos propiedad del conglomerado global, y de la compañía farmacéutica GlaxoSmithKline, de la que era consejero no ejecutivo.
|
Reuters
GSK ups lung drug bet by buying more of Theravance
LONDON (Reuters) - GlaxoSmithKline bet another $212.9 million on the success of lung drug Relovair on Monday by raising its stake in U.S. biotech firm Theravance - its partner on the new medicine -...
|
lesoir
07:01 Licenciement collectif chez GSK Pharmaceuticals
Quarante-cinq personnes sont concernées par le plan social annoncé par la direction de GlaxoSmithKline qui veut restructurer cette branche de GSK en Belgique. ...lire la suitehistoires liées06:58 Le Soir pas autorisé à couvrir les élections birmanes07:25 Miami : Venus Williams se qualifier pour les quarts de finale08:02 NBA : les résultats de lundi08:11 L’Eurochallegne FIBA de basket : la final...
|
Daily Mail
Glaxo's £500m investment to create 1,000 jobs for Britain's pharmaceutical industry
Research tax cuts included in the Budget prompted GlaxoSmithKline to announce the building of a new factory at Ulverston, in Cumbria - its first in 40 years
|
Number10
PM welcomes 1,000 new jobs at GlaxoSmithKline
PM: "a major investment that will create many highly skilled jobs and provide a great boost to the economy"
|
BBC
Glaxo invests £500m in UK sites
UK drugmaker GlaxoSmithKline says it will invest £500m in manufacturing in the nation, including building a new factory in Ulverston, Cumbria.
|
La Voix du Nord
Angleterre: GSK confirme un investissement de 600 millions d´euros, jusqu´à 1.000 emplois créés
Le groupe pharmaceutique britannique GlaxoSmithKline (GSK) a confirmé jeudi son intention d'investir 600 millions d'euros au Royaume-Uni, avec la création d'un site de production et jusqu'à 1.000 nouveaux emplois.histoires liéesEn grande forme en 2011, le shopping détaxé en France a doublé en cinq ansDepuis la crise, un tiers des PME-PMI font voyager leurs cadres en low-costConcurrence: enquête...
|
TechCrunch
Index Launches Its First Life Sciences Fund: $200M And Partnering With Glaxo and Johnson & Johnson
Index Ventures may be best known on these pages for its technology investments, but today it launched a new fund that points to how the company is willing to put its money into other examples of strong innovation. The life sciences fund will see Index put in $100 million of its own capital, and have it matched by $50 million each from big pharma leaders GlaxoSmithKline and Johnson & Johnson...
|
AP
FDA panel backs Glaxo drug for rare cancer
WASHINGTON (AP) -- A panel of cancer experts rejected an experimental Merck drug for a rare form of cancer on Tuesday while recommending approval of a GlaxoSmithKline treatment for the same disease. Neither drug appears to help patients live longer, but panelists said Glaxo's Votrient helped delay tumor growth in the most vulnerable patients....
|
Scientific American
Faster-Acting Experimental Antidepressants Show Promise
Antidepressants restore well-being to many people, but sometimes at the cost of such side effects as weight gain or loss of interest in sex. And these side effects can be just part of the frustration. As Robin Marantz Henig wrote in " Lifting the Black Cloud ," in the March issue of Scientific American , the drugs that have long dominated the market--the selective serotonin reuptake inhibito...
|
Telegraph
New cancer drugs being held back to save Government money, says GlaxoSmithKline boss
The head of Britain biggest drugs company has accused the Government of systematically delaying the introduction of new cancer drugs in order to save money.
|
BBC
Ministers deny delaying new drugs
Ministers reject claims from the UK's biggest drug firm GlaxoSmithKline that new cancer treatments are being delayed to save money.
|
Daily Mail
Cancer drugs are being held back so the Government can save money, says GlaxoSmithKline boss
GlaxoSmithKline chief executive Sir Andrew Witty warned that ministers were making false economies as they tried to grapple with the deficit in public finances.
|
Telegraph
Argentines burn tyres and Union Jack at anti-British protest
Activists held an anti-British demonstration and burned tyres and a Union Jack flag outside the gates of British drugmaker GlaxoSmithKline near Buenos Aires as tensions between Argentina and Britain rise over the disputed Falkland Islands.
|
Irish Times
GSK emptying bank accounts to limit euro zone exposure
GLAXOSMITHKLINE is emptying out tens of millions of euro each day from its bank accounts in Europe’s more fragile countries to minimise the risk of exposure to a regional banking or financial crisis.
|
FT
GlaxoSmithKline: word to the wise
GSX is in decent shape. But as it further expands abroad, investors should watch not only the underlying numbers, but the headline ones too
|
BBC
Profits surge at GlaxoSmithKline
UK drugmaker GlaxoSmithKline announces profits of £1.9bn for the three months to the end of December, up from a £193m loss a year previously.
|
physorg
GlaxoSmithKline says annual profits triple to £5.26 bln
British drugmaker GlaxoSmithKline said Tuesday that net profits more than tripled in 2011 compared with the previous year, as large efficiency savings offset falling revenues.
|
politico
Remainders: Weakened
Slate explains Twitter's new censorship policy, the talk of the Twitterverse today and a new challenge for global Internet firms.
Romney's debate coach wins the week.
Gingrich goes passive.
He looks like he might be finished.
Conservatives criticize Drudge for going against him.
James Murdoch quits GlaxoSmithKline board.
CTO Aneesh Chopra leaves the White House.
Yale Daily News sits on Patrick...
|
Irish Times
Clegg visits research lab in UCD
HE DIDN’T go so far as to pose in a white lab coat, but British deputy prime minister Nick Clegg made a brief visit to the laboratories of UCD yesterday as part of a meet-and-greet with charities, researchers and pharmaceutical giant GlaxoSmithKline.
|
Telegraph
GlaxoSmithKline fined over trials on the babies of Argentinian poor
GlaxoSmithKline, Britain's biggest drug firm, has been fined by an Argentine court over clinical trials of a pneumonia vaccine which was tested on thousands of babies from poor families.
|
DerSpiegel
Kinder-Impfstudie in Argentinien: Richter verurteilt GlaxoSmithKline zu Geldstrafe
Wegen Ungereimtheiten bei einer klinischen Studie in Argentinien muss GlaxoSmithKline ein Bußgeld bezahlen. Der Konzern hatte einen Impfstoff an Kindern getestet - teilweise ohne gültige Einverständniserklärung der Familien. Jetzt will das Unternehmen in Berufung gehen.
|
Les Echos
Tests avec enfants pauvres d'Argentine : amende pour un laboratoire britannique
[[343613]] BUENOS AIRES (AFP) : Le laboratoire britannique GlaxoSmithKline devra payer une amende de 230.000 dollars (177.000 euros) pour des irrégularités commises pendant des tests de vaccins sur des enfants de familles pauvres en Argentine, a-t-on appris de source judiciaire. Des failles ont été...
|
CNN
Argentina fines drug company over vaccine trial
A medical group in Argentina is asking for more drug-testing regulations in the South American country after a officials fined pharmaceutical company GlaxoSmithKline for alleged irregularities in a pediatric pneumonia vaccine trial.
|
APA-OTS
GSK unterstützt Wohngemeinschaft für Mädchen
Utl.: Mehr als 50 kg selbstgebackene Weihnachtskekse - 1.000,- Euro
an Sterntalerhof durch Geschenkversteigerung =
Wien (OTS) - Am "Orange Day" stellt GlaxoSmithKline weltweit alle
MitarbeiterInnen frei, die in ihrem Land einen persönlichen sozialen
Beitrag leisten wollen. Das GSK-Team ...
|
La Voix du Nord
GSK à Saint-Amand : cinq ans après, l´investissement et les emplois sont là
Le plus gros investissement industriel dans la région depuis Toyota. C'était encore dans le Valenciennois : le 29 septembre 2006, GlaxoSmithKline, groupe pharmaceutique britannique, annonçait qu'il avait choisi Saint-Amand, où il avait racheté en 2002 le laboratoire Stérilyo, pour construire sa nouvelle plate-forme de production de vaccins. GSK l'a inaugurée hier.
|
Los Angeles Times
SEC accuses Stiefel Laboratories of defrauding employee shareholders
The Securities and Exchange Commission has accused a subsidiary of GlaxoSmithKline and the subsidiary’s former chief executive of defrauding employees and other shareholders by buying back the company’s private stock at severely undervalued prices.
In a lawsuit filed in federal court in Florida, the SEC accused Stiefel Laboratories Inc. and former chairman and Chief Executive Charles Stiefel of...
|
Reuters
GSK weighs final bids in OTC drugs sale -sources
LONDON, Nov 14 (Reuters) - GlaxoSmithKline is
assessing final bids for a clutch of its non-prescription drugs,
keeping the process on track for the selection of a buyer by the
end of the year, people...
|
science blogs
Kommentar von Andreas P. bei "Impfungen sind wichtig!" (Astrodicticum Simplex) am 12.11.2011
halb OT:
weil hier wieder die Mär von den armen Pharmaunternehmen, die sich fast in den Ruin forschen, aufkam, mal ein paar Zahlen zum Thema (Name, Umsatz in Mrd. €, Gewinn vor Steuern, bezogen auf Umsatz).
1. Pfizer, 34.1, 23%
2. GlaxoSmithKline, 26.2, 31%
3. Sanofi-Aventis, 24.9, 11%
4. Roche, 21.7, 25%
5. Novartis, 19.3, 23%
6. AstraZeneca, 18.5, 28%
7. Johnson&Johnson, 17.2, 27%
8. Me...
|
WHO
WHO welcomes GlaxoSmithKline support to fight intestinal worms in children
9 September 2011 -- Today, WHO acknowledges the generous commitment by GlaxoSmithKline (GSK) to donate 400 million more deworming tablets - albendazole - a year over the next five years to help children in deprived communities. This donation comes on top of the 600 million tablets of albendazole already being used in the Global Programme to Eliminate Lymphatic Filariasis.
|
You need to upgrade your Flash Player
# |
Countries |
MIX |
| 1 | United States | 1.825 |
| 2 | Romania | 0.400 |
| 3 | India | 0.390 |
| 4 | Canada | 0.070 |
| 5 | Norway | 0.040 |
| 6 | United Kingdom | 0.035 |
| 7 | Denmark | 0.030 |
| 8 | Poland | 0.020 |
| More Countries >> |
You need to upgrade your Flash Player
# |
Media |
MIX |
| 1 | Realitatea TV | 0.400 |
| 2 | Fox Business Network | 0.300 |
| 3 | drugs.com | 0.300 |
| 4 | marketwatch.com | 0.200 |
| 5 | CNBC | 0.150 |
| 6 | Bloomberg | 0.125 |
| 7 | Bergen County Record | 0.120 |
| 8 | WALL STREET JOURNAL USA | 0.120 |
| 9 | moneycontrol | 0.120 |
| 10 | Businesstoday | 0.120 |
| 11 | businessweek | 0.105 |
| 12 | abc live | 0.100 |
| 13 | zdnet | 0.100 |
| 14 | webmd.com | 0.060 |
| 15 | cnet | 0.060 |
| 16 | seekingalpha.com | 0.050 |
| 17 | The Globe and Mail | 0.050 |
| 18 | Dnaindia | 0.050 |
| 19 | MSNBC | 0.050 |
| 20 | MIT´s technologyreview.com | 0.045 |
| More Media >> |
You need to upgrade your Flash Player
# |
Languages |
MIX |
| 1 | English | 2.320 |
| 2 | Romanian | 0.400 |
| 3 | Norwegian | 0.040 |
| 4 | Danish | 0.030 |
| 5 | Polish | 0.020 |
| 6 | Portuguese | 0.000 |
| 7 | German | 0.000 |
| 8 | Finnish | 0.000 |
| 9 | Chinese | 0.000 |
| 10 | Italian | 0.000 |
| 11 | Korean | 0.000 |
| 12 | Dutch | 0.000 |
| 13 | French | 0.000 |
| 14 | Indonesian | 0.000 |
| 15 | Turkish | 0.000 |
| 16 | Spanish | 0.000 |
| 17 | Swedish | 0.000 |
| 18 | Russian | 0.000 |
| 19 | Czech | 0.000 |
| 20 | Japanese | 0.000 |
| More Languages >> |
# |
Lists |
| 1 | Top 100 European Companies |
| 2 | FTSE 100 index UK |
